NovoCure Limited (NVCR)

NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	525.66	509.34	537.84	535.03	494.37	351.32
Revenue Growth (YoY)	0.61%	-5.30%	0.53%	8.23%	40.72%	41.62%
Cost of Revenue	132.36	128.28	114.87	114.88	106.5	88.61
Gross Profit	393.3	381.06	422.97	420.15	387.87	262.71
Selling, General & Admin	392.49	390.87	306.41	263.18	225.45	184.62
Research & Development	214.96	223.06	206.09	201.3	132.01	79
Operating Expenses	607.45	613.93	512.5	464.49	357.46	263.63
Operating Income	-214.14	-232.87	-89.52	-44.33	30.4	-0.91
Interest Expense / Income	-41.84	-41.13	-7.68	7.74	12.3	7.91
Pretax Income	-172.3	-191.74	-81.85	-52.08	18.1	-8.82
Income Tax	20.44	15.3	10.69	6.28	-1.71	-1.59
Net Income	-192.74	-207.04	-92.53	-58.35	19.81	-7.23
Shares Outstanding (Basic)	107	106	105	103	101	97
Shares Outstanding (Diluted)	107	106	105	103	109	97
Shares Change	1.51%	1.65%	1.19%	-5.00%	11.97%	5.89%
EPS (Basic)	-1.80	-1.95	-0.88	-0.56	0.20	-0.07
EPS (Diluted)	-1.80	-1.95	-0.88	-0.56	0.18	-0.07
Free Cash Flow	-120.97	-100.43	9.43	58.59	84.18	16.14
Free Cash Flow Per Share	-1.13	-0.94	0.09	0.57	0.83	0.17
Gross Margin	74.82%	74.81%	78.64%	78.53%	78.46%	74.78%
Operating Margin	-40.74%	-45.72%	-16.64%	-8.29%	6.15%	-0.26%
Profit Margin	-36.67%	-40.65%	-17.20%	-10.91%	4.01%	-2.06%
Free Cash Flow Margin	-23.01%	-19.72%	1.75%	10.95%	17.03%	4.59%
Effective Tax Rate	-	-	-	-	-9.42%	-
EBITDA	-203.08	-221.9	-78.9	-34.08	39.55	7.55
EBITDA Margin	-38.63%	-43.57%	-14.67%	-6.37%	8.00%	2.15%
Depreciation & Amortization	11.06	10.97	10.62	10.25	9.15	8.46
EBIT	-214.14	-232.87	-89.52	-44.33	30.4	-0.91
EBIT Margin	-40.74%	-45.72%	-16.64%	-8.29%	6.15%	-0.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).